Leon-Ferre and colleagues describe an interesting case of an 87-year-old man with a poorly differentiated stage IV squamous cell carcinoma of the esophagus, treated in the progression scenario with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy. This chemotherapy regimen is used primarily in patients with localized or resected metastatic colorectal adenocarcinoma.The administration of FOLFOX requires a central catheter in order to avoid hospitalization and to maintain an efficient method of chemotherapy administration, thereby avoiding extravasation of the drugs. Although it is difficult to give an accurate measurement of its incidence, extravasation has been reported to occur in 0.1—6% of cases, and in approximately 3% of infusions through central venous access ports.
展开▼
